RxDoctor Payments DataLook up a doctor →

Oliver Gregory, MD

Psychiatry · Chattanooga, TNNPI 1588772545

Payments from drug & device makers

$12,914in general payments, 2019–2025

Across 684 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$984
  • plus $6K from 28 others

What the payments were for

  • Food & beverage$12,858100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,914 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$185,708
Medicare patients
303
Services billed
2,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$235,300
VraylarCariprazine Hcl38$63,884
BelsomraSuvorexant104$54,302
AuvelityDextromethorphan Hbr/Bupropion36$46,009
RexultiBrexpiprazole11$26,602
SpravatoEsketamine Hcl22$26,564
TrintellixVortioxetine Hydrobromide28$20,483
Lurasidone Hcl52$12,599
Desvenlafaxine Succinate ErDesvenlafaxine Succinate84$10,396
VyvanseLisdexamfetamine Dimesylate13$7,074
Duloxetine Hcl164$4,534
Bupropion XlBupropion Hcl123$4,035
Buspirone Hcl147$3,914
Mirtazapine135$3,784
Aripiprazole84$3,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,347$235,30029 claims
AbbVieVraylar$984$63,88438 claims
MerckBelsomra$174$54,302104 claims
Axsome Therapeutics, Inc.Auvelity$312$46,00936 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$399$27,55741 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,066$26,60211 claims
Johnson & JohnsonSpravato$1,093$26,56422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →